https://www.healthcaretribunefrance.com/article/913199221-ipsen-presents-first-in-class-late-breaking-phase-ii-corabotase-data-in-glabellar-lines-showing-sustained-duration-of-effect-reinforced-by Healthcare Tribune France en PressRelease 2026-05-16T12:00:00+00:00 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg https://www.healthcaretribunefrance.com/article/913199224-ipsen-pr-sente-les-derniers-r-sultats-d-une-tude-de-phase-ii-sur-la-corabotase-premi-re-de-sa-classe-concernant-les-rides-glabellaires-montrant Healthcare Tribune France en PressRelease 2026-05-16T12:00:00+00:00 Ipsen présente les derniers résultats d'une étude de phase II sur la corabotase, première de sa classe, concernant les rides glabellaires, montrant une durée d'effet prolongée et un niveau de satisfaction constamment élevé chez les patients https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ https://www.healthcaretribunefrance.com/article/912171132-cb-therapeutics-after-the-executive-order-supply-becomes-the-binding-constraint-on-psychedelic-medicine Healthcare Tribune France en PressRelease 2026-05-15T12:00:00+00:00 CB Therapeutics: After the Executive Order, Supply Becomes the Binding Constraint on Psychedelic Medicine